Vaccination

Boehringer Ingelheim Vetmedica, Inc. (BIVI) vaccines deliver sustainable, whole-herd PRRS control through all phases of production. BIVI has multiple modified-live vaccines for PRRS, which have demonstrated cross-protection for both the reproductive and respiratory forms of the disease. When determining a vaccine protocol, it is important to use the right vaccine at the right place and time.

Below are possible vaccination protocols and corresponding vaccines available from BIVI. Work with your herd veterinarian to determine the protocol that best meets the needs of your operation.

Piglets Gilts/Sows, Not Pregnant
and Prior to Breeding
Breeding Herd –
Whole-Herd Program
One dose at or around weaning Vaccination of non-pregnant
animals prior to breeding
Mass vaccination of all sows and gilts in the breeding herd (any phase of production) every three to four months for protection against the reproductive form of PRRS
Ingelvac PRRS® MLV
Ingelvac PRRS® ATP
3FLEX®
Ingelvac PRRS® MLV
Ingelvac PRRS® ATP
3FLEX®
ReproCyc® PRRS-PLE
Ingelvac PRRS® MLV
  • VACCINE OPTIONS

    Boehringer Ingelheim Vetmedica, Inc. offers the most comprehensive line of PRRS vaccines, so you can choose the product that best fits the needs of your farm. The following list includes US licensed vaccines; talk to your herd veterinarian about global labels.

    Ingelvac PRRS MLV 50BoxBot1 WRI
    Ingelvac PRRS ATP Box Vial 50dose100mL
    Ingelvac PRRS ATP Box Vial 50dose100mL
    ReproCyc PRRS PLE Box Vial 20Dose100mL

    Ingelvac PRRS® MLV

    A leading modified-live PRRS vaccine that is:

    • Trusted and field proven
    • Unique in its ability to be used in pigs (3 weeks or older), gilts and sows at any stage of production
    • Known for demonstrating cross-protection
    • Aids in the prevention of respiratory disease, and aids in the reduction of reproductive disease caused by PRRS virus

    Learn More

    Ingelvac PRRS® ATP

    A modified-live PRRS vaccine that is:

    • Trusted and field proven
    • Developed from a different parent strain in comparison to Ingelvac PRRS® MLV
    • Known for demonstrating cross-protection1
    • Effective in reducing reproductive failure and respiratory disease due to PRRS virus1,2,3

    Learn More


    1. Holtkcamp, D, Kliebenstein JB, Neumann EJ, et al. 2013. Assessment of the economic impact of porcine reproductive and respiratory syndrome virus on United States pork producers. J Swine Health Prod 2013:21(2): 72–84.
    2. Roof M, et al. Efficacy of modified-live virus porcine reproductive and respiratory virus vaccines against heterologous respiratory challenge. 2003, IPVS, p. 117.
    3. Jordan D, Layton S, Philips R, Genzow M. Modified-live PRRS vaccination provides heterologous protection against virulent 1-18-2 challenge. 2009. Leman Conference.

    3FLEX®

    The only single-dose, three-way vaccine licensed by USDA that:

    • Provides customized control for three key swine diseases – PRRS, porcine circovirus type 2 (PCV2) and M. hyopneumoniae
    • Requires fewer injections
    • Has been proven effective
    • Contains the unique ImpranFLEX® adjuvant

    Learn More

    ReproCyc® PRRS–PLE

    A convenient pre-breeding combination vaccine that is:

    • Composed of a modified-live PRRS component and a nonvirucidal, inactivated Parvo, Leptospira and Erysipelothrix rhusiopathiae diluent component
    • Proven to cross-protect against homologous and heterologous (Lelystad virus) PRRS challenge
    • Convenient and cost-effective
    • Safe, proven and effective

    Learn More

  • Benefits of Vaccination

    Multiple controlled and field-based studies have demonstrated that Ingelvac PRRS® vaccines provide two benefits to producers:

    1. Direct benefit – The effects of infection are reduced and there is a subsequent improvement in health and performance.6
    2. Indirect benefit – Studies show that Ingelvac PRRS® vaccines can reduce shedding/transmission of wild-type PRRS virus.
    DIRECT BENEFIT
    INDIRECT BENEFIT

    Pigs challenged with the PRRS virus experience lower average daily gain and higher mortality rates, with an estimated profit loss of $4.32 per pig.1 However, extensive controlled and field-based studies have demonstrated that Ingelvac PRRS® vaccines provide a direct benefit to pigs and producers, including:

    • Cross-protection against a variety of field strains2,3,4,5
    • Reduced mortalities1,6
    • Improved average daily gain6

    To help ensure ongoing benefits, Boehringer Ingelheim Vetmedica, Inc. continues to evaluate the effectiveness of Ingelvac PRRS® MLV against the most current strains of PRRS virus to provide you with up-to-date information.

    Learn More

    In addition to reducing clinical disease, studies demonstrate that Ingelvac PRRS® can provide an indirect benefit by reducing shedding/transmission of wild-type PRRS virus.

    In a study comparing pigs vaccinated with Ingelvac PRRS® to non-vaccinated controls, vaccinated pigs had a significant reduction in the frequency of wild-type virus shedding (measured by virus detected in the air) and a 30-day shorter duration of shedding compared to the non-vaccinated pigs.7

    Dr. Scott Dee (Pipestone Veterinary Services) discussed the impact of PRRS transmission and the benefits of reduced shedding. Watch to learn more.

    Learn more

    1. Holtkcamp, D, Kliebenstein JB, Neumann EJ, et al. 2013. Assessment of the economic impact of porcine reproductive and respiratory syndrome virus on United States pork producers. J Swine Health Prod 2013:21(2): 72–84.
    2. Roof M, et al. Efficacy of modified-live virus porcine reproductive and respiratory virus vaccines against heterologous respiratory challenge. 2003, IPVS, p. 117.
    3. Jordan D, Layton S, Philips R, Genzow M. Modified-live PRRS vaccination provides heterologous protection against virulent 1-18-2 challenge. 2009. Leman Conference.
    4. Roof MB, Vaughn E, Rurkhart K, Johnson W. Meta-analysis of 16 modified-live PRRS vaccination challenge studies. International Symposium of Emerging and Reemerging Swine Diseases, 2007.
    5. Patterson A, Victoria J, Jordan D, et al. Modified-live PRRSv vaccination is efficacious following challenge with eight genetically diverse PRRSv isolates. Leman Conference, 2013.
    6. Oropeza A, Kolb J, Philips R, and White M. A summary of three large-scale systems-based PRRS control projects.
    7. Wetzell T, Cano J, Rustvold J. Reduction of Wild-Type PRRS Virus Shedding in Aerosol of Growing Pigs by Modified-Live Virus Vaccination at Weaning. 2013 Pipestone Research Committee, Leman Conference, p. 196.
  • Vaccination Recommendations
    Breeding Herd Tested at
    Weaning
    (pos/neg)*
    Grow- Finish
    Exposure
    Vaccinate
    Breeding Herd
    for PRRS?
    Vaccinate
    Growing Pigs
    for PRRS?
    +
    (Positive and
    unstable)
    + + YES
    (attain stability)
    YES**
    +
    (Positive and
    stable)
    - + YES
    (maintain stability)
    YES
    +
    (Positive and
    stable)
    - - YES
    (maintain stability)
    NO
    -
    (Negative)
    - + Not
    Recommended
    YES
    -
    (Negative)
    - - Not
    Recommended
    NO

    *PRRS PCR assessment of pigs at weaning.
    **Studies demonstrate the benefit of vaccinating growing pigs when PRRS virus prevalence is low
    (<20% positive PCR pools). This decision should be made under the direct consultation of a veterinarian.1,2

    Gilts should be vaccinated twice — 30 days apart — with the last dose occurring four weeks prior to entry into the breeding herd.

    Always work with your herd veterinarian when developing vaccination protocols. Read and follow label directions.

    References:
    1 Waddell J. et al. Modified-live PRRS virus vaccination of nursery pigs as an essential component of a comprehensive PRRS control program. IPVS, 2008.
    2 Boehringer Ingelheim Vetmedica Inc., internal data. Unpublished at this time.